Follow on Google News News By Tag Industry News News By Place Country(s) Industry News
Follow on Google News | Global Pneumonia Vaccines Market to reach a market size of $9.6 billion by 2025- KBV ResearchThe Global Pneumonia Vaccines Market size is expected to reach $9.6 billion by 2025, rising at a market growth of 5.1% CAGR during the forecast period.
By: KBV Research The North America market dominated the Global Pneumococcal Conjugate Vaccine (PCV) Market by Region in 2018, growing at a CAGR of 2.8 % during the forecast period. The Europe market is expected to witness a CAGR of 3.6% during (2019-2025). Additionally, The Asia Pacific market is expected to witness a CAGR of 5.3% during (2019-2025). The Prevnar 13 market dominated the Global Pneumonia Vaccines Market by Product Type in 2018, growing at a CAGR of 4.1 % during the forecast period. The Synflorix market is expected to witness a CAGR of 7.5% during (2019-2025). Additionally, The Pneumovax23 market is expected to witness highest CAGR of 8.5% during (2019-2025). The Distribution Partner Companies market dominated the Global Pneumonia Vaccines Market by Distribution Channel in 2018, growing at a CAGR of 4.3 % during the forecast period. The Non-Governmental Organizations (NGO) market is expected to witness a CAGR of 6% during (2019-2025). Full Report: https://www.kbvresearch.com/ The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Glaxosmithkline Plc. (GSK), LG Corporation, Panacea Biotec Limited, Pfizer, Inc., Pnuvax Incorporated, Poonawalla Investments & Industries Pvt. Ltd., Shenzhen Kangtai Biological Products Co., Ltd., SK Holdings Co., Ltd., Walvax Biotechnology Co., Ltd. and MERCK & CO., Inc. Global Pneumonia Vaccines Market Segmentation By Vaccine Type Pneumococcal conjugate vaccine (PCV) Pneumococcal polysaccharide vaccine (PPSV/PPV) By Product Type Prevnar 13 Synflorix Pneumovax23 By Sector Public sector Private sector By Distribution Channel Distribution partner companies Non-governmental Organizations (NGO) Government Authorities By Geography North America US Canada Mexico Rest of North America Europe Germany UK France Russia Spain Italy Rest of Europe Asia Pacific China Japan India South Korea Singapore Malaysia Rest of Asia Pacific LAMEA Brazil Argentina UAE Saudi Arabia South Africa Nigeria Rest of LAMEA Companies Profiled Glaxosmithkline Plc. (GSK) LG Corporation Panacea Biotec Limited Pfizer, Inc. Pnuvax Incorporated Poonawalla Investments & Industries Pvt. Ltd. Shenzhen Kangtai Biological Products Co., Ltd. SK Holdings Co., Ltd. Walvax Biotechnology Co., Ltd. Merck & Co., Inc. End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|